Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | EIK1001 |
Trade Name | |
Synonyms | BDB-001|BDB 001|EIK-1001|EIK 1001|BDB001 |
Drug Descriptions |
EIK1001 is a TLR 7/8 agonist, which potentially induces inflammatory responses and activation of immune cells, leading to antitumor activity (J Clin Oncol 42, 2024 (suppl 16; abstr 2521). |
DrugClasses | TLR7 Agonist 12 TLR8 Agonist 9 |
CAS Registry Number | NA |
NCIT ID | C156395 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Atezolizumab + EIK1001 | Atezolizumab EIK1001 | 0 | 2 |
Carboplatin + EIK1001 + Paclitaxel + Pembrolizumab | Carboplatin EIK1001 Paclitaxel Pembrolizumab | 0 | 1 |
Carboplatin + EIK1001 + Pembrolizumab + Pemetrexed Disodium | Carboplatin EIK1001 Pembrolizumab Pemetrexed Disodium | 0 | 1 |
EIK1001 | EIK1001 | 0 | 2 |
EIK1001 + Pembrolizumab | EIK1001 Pembrolizumab | 0 | 1 |